tirzepatide cardiovascular outcome trial Original Article: Outcomes with versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT trial) https://t.co/4BWhSd0ZCC #Endocrinology #Cardiology Tirzepatide compared with semaglutide and

These local responses occur because tirzepatide activates GLP-1 receptors in subcutaneous nerve endings and immune cells

Baseline estimated renal function was normal (eGFR 90 mL/min/1.73m2) in 63.1%, mildly impaired (eGFR 60 to 90 mL/min/1.73m2) in 34.3%, and moderately impaired (eGFR 30 to 60 mL/min/1.73m2) in 2.5% of the patients

These non-scale victories motivate continued adherence even when weight loss temporarily slows during plateau periods

If the FDA moves to reclassify the peptides so that compounding pharmacies can make them, it will be through a formal rulemaking process that could stretch into next year or 2028

The starting dose is 0.25 mg once weekly for four weeks, followed by 0.5 mg for four weeks, then 1 mg for four weeks, then 1.7 mg for four weeks, and finally 2.4 mg once weekly as the maintenance dose